ASH 2022 Leukemia Highlights

CME

Key Studies in Leukemias: Independent Conference Coverage of ASH 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 21, 2023

Expiration: March 20, 2024

Amir T. Fathi
Amir T. Fathi, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed
Introduction

At the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, new clinical trial data on acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) were reported. In this module, Eunice Wang, MD, and Amir Fathi, MD, review and discuss the clinical implications of key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with leukemia do you provide care for in a typical month?

You are discussing the results of the phase I/II study of azacitidine/venetoclax/magrolimab triplet therapy in patients with newly diagnosed or relapsed/refractory (R/R) AML with your oncology fellow in clinic. Which of the following would you tell her based on the results reported at ASH 2022?

Which of the following was reported regarding differentiation syndrome (DS) with ziftomenib from the phase Ib KOMET-001 study in patients with R/R AML and KMT2A or NPM1 mutations?

Based on results of the ECOG-ACRIN E1910 trial, which of the following consolidation regimens would you recommend for a young, fit adult with newly diagnosed Philadelphia chromosome (Ph)–negative B-cell ALL (B-ALL) who is measurable residual disease (MRD) negative?

Based on evidence from the ASC4MORE trial, which of the following patients with chronic-phase CML would you consider for potential enrollment on a clinical trial with asciminib?